Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin
β Scribed by Ishii, Eiichi ;Hara, Toshiro ;Ohkubo, Kenshi ;Matsuzaki, Akinobu ;Takeuchi, Takami ;Veda, Kohji
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 389 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Effective treatment of the elderly patients (265 years) with acute nonlymphocytic leukemia (ANLL) remains elusive and controversial. In the present study, single-agent Cytosine Arabinoside (AM-C) was administered at an intermediate dose level (500 mg/m2 intravenously [I.V.] I-hour infusion q12 hours
## Abstract Three groups of children with acute lymphoblastic leukemia (ALL) were treated with intermittent cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP). Group A (no prior relapse) and Group B (prior singleβagent relapse) received COAP after 12 months on another chemot